http://www.boydgraves.com/flowchart/ http://www.boydgraves.com/news/011004.doc
Method of curing AIDS with tetrasilver tetroxide molecular crystal > devices > > > Abstract > The diamagnetic semiconducting molecular crystal tetrasilver > tetroxide (Ag.sub.4 O.sub.4) is utilized for destroying the AIDS > virus, destroying AIDS synergistic pathogens and immunity suppressing > moieties (ISM) in humans. A single intravenous injection of the > devices is all that is required for efficacy at levels of about 40 > PPM of human blood. The device molecular crystal contains two mono > and two trivalent silver ions capable of "firing" electrons capable > of electrocuting the AIDS virus, pathogens and ISM. When administered > into the bloodstream, the device electrons will be triggered by > pathogens, a proliferating virus and ISM, and when fired will > simultaneously trigger a redox chelation mechanism resulting in > divalent silver moieties which chelate and bind active sites of the > entities destroying them. The devices are completely non-toxic. > However, they put stress on the liver causing hepatomegaly, but there > is no loss of liver function. --- The present invention is based on concepts previously elucidated in > applicant's U.S. Pat. No. 5,336,499 which discloses the destruction > and inhibition of bacteria, algae and the AIDS virus in nutrient life > supporting systems by using said silver oxide devices. Example 3 of > said patent discloses that 18 PPM of said crystal devices could > totally suppress the AIDS virus (page 6, line 5). Subsequent to the > filing of the aforementioned patent, further testing revealed > complete 100% destruction of the AIDS virus in vitro at 20 PPM, and > the fact that said devices were harmless when ingested and inhaled, > being non-toxic. > > Encouraged by these evaluations and successes, applicant obtained > permission to evaluate the crystals in vitro against murine acquired > immune deficiency syndrome (MAIDS). Only one facility in the State of > Israel is licensed for these evaluations, namely, the Kaplan Hospital > in Rehovot, Israel, which is affiliated with the Hebrew University- > Hadassah Medical School where said evaluations were done. > > The initial evaluations entailed experimenting with various silver > moieties cited in applicant's aforementioned patent, concentrations, > non-reactive buffers and modes of administration. After about 18 > months of judicious efforts and initial failures, success was finally > achieved in destroying the MAIDS virus in C57BL mice with a single > intravenous injection. The results of this test program comprise > Example 5 of U.S. Pat. No. 5,336,499. After success with mice, the > inventor was able to test the efficacy of said devices on two select > etiological groups of terminal AIDS patients in a clinic in > Tegucigalpa, Honduras, Central America. - etc discussed on Hulda Clark site http://groups.yahoo.com/group/DrClark/ -- The Silver List is a moderated forum for discussing Colloidal Silver. Instructions for unsubscribing are posted at: http://silverlist.org To post, address your message to: silver-list@eskimo.com Silver List archive: http://escribe.com/health/thesilverlist/index.html Address Off-Topic messages to: silver-off-topic-l...@eskimo.com OT Archive: http://escribe.com/health/silverofftopiclist/index.html List maintainer: Mike Devour <mdev...@eskimo.com>
